<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434031</url>
  </required_header>
  <id_info>
    <org_study_id>CETRA</org_study_id>
    <secondary_id>EudraCT number: 2006-003993-85</secondary_id>
    <nct_id>NCT00434031</nct_id>
  </id_info>
  <brief_title>CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer</brief_title>
  <acronym>CETRA</acronym>
  <official_title>Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the rate of pathologic complete response when giving
      docetaxel and trastuzumab followed by caelyx (liposomal doxorubicin), cyclophosphamide and
      trastuzumab before surgery in treating women with operable or locally advanced HER-2 positive
      breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy in association with trastuzumab, a monoclonal antibody, given before surgery,
      has been shown to reduce tumor size and permit better resection of HER-2 positive breast
      cancers. This study will evaluate the activity of a neoadjuvant treatment with docetaxel and
      trastuzumab given every 3 weeks for 4 cycles, followed by the combination of caelyx,
      cyclophosphamide and trastuzumab every 3 weeks for 4 cycles. Patients will undergo breast
      cancer surgery 2-5 weeks after the completion of neoadjuvant therapy. Adjuvant therapy after
      surgery will be given according to existing guidelines, and will include an additional 10
      cycles of trastuzumab.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of enrollment
  </why_stopped>
  <start_date>September 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete pathologic response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity of neoadjuvant treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive ability of noninvasive diagnostic methods for results of neoadjuvant treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal doxorubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of breast cancer

          -  Stage II-IIIB (T0-1-2-3-4-N+-M0 or T2-3-4-N0-M0; according to TNM AJCC classification,
             2002)

          -  Hyperexpression of HER-2/neu (HercepTest 3+ or positive FISH test)

          -  Age&gt; 18 e &lt; 65 years

          -  Left ventricular ejection fraction (LVEF) &gt; or = 55%

          -  ECOG Performance Status 0-2

          -  Neutrophils &gt; or = 2000/mm続, platelets &gt; or = 100.000/mm続 , hemoglobin &gt; or = 10
             g/dl), GOT, GPT and bilirubin &lt; 1.25 x the upper normal limit, creatinine &lt; 1.25 x the
             upper normal limit.

          -  Life expectancy &gt; 3 months

          -  Signed informed consent.

        Exclusion Criteria:

          -  Any prior treatment for breast cancer

          -  Metastatic disease (M1)

          -  Performance status (ECOG) &gt; or = 3

          -  Current malignancy or history of prior malignancy within past 10 years (with the
             exception of adequately treated non-melanoma skin cancer and carcinoma in situ of the
             uterine cervix)

          -  Neutrophils &lt; 2.000/mm続 , platelets &lt; 100.000/mm続 , hemoglobin &lt; 10 g/dl.

          -  Creatinine &gt; 1.25 x the upper normal limit

          -  GOT and/or GPT and/or bilirubin &gt;1.25 x the upper normal limit.

          -  Concomitant conditions that, in the investigator's opinion, contraindicate the use of
             the drugs in the protocol.

          -  Congestive heart failure or history of congestive heart failure, unstable angina
             pectoris, myocardial infarction, clinically significant valvulopathy or uncontrolled
             arrhythmias

          -  Active infection

          -  Incapacity or refusal to provide informed consent.

          -  Inability to comply with follow up

          -  Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Matteis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Medical Oncology C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe D'Aiuto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Division of Surgical Oncology A</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples, Clinical Trials Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <keyword>locally advanced</keyword>
  <keyword>stage II</keyword>
  <keyword>stage IIIa</keyword>
  <keyword>stage IIIb</keyword>
  <keyword>HER-2 positive</keyword>
  <keyword>primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

